Beyond Air Net Income 2016-2021 | XAIR

Beyond Air net income from 2016 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Beyond Air Annual Net Income
(Millions of US $)
2021 $-23
2020 $-20
2019 $-7
2017 $-18
2016 $-4
2016 $-4
2015 $-3
2015 $-3
Beyond Air Quarterly Net Income
(Millions of US $)
2021-06-30 $-7
2021-03-31 $-5
2020-12-31 $-6
2020-09-30 $-5
2020-06-30 $-7
2020-03-31 $-5
2019-12-31 $-5
2019-09-30 $-4
2019-06-30 $-6
2019-03-31 $-0
2018-12-31 $-2
2018-09-30 $-2
2018-06-30 $-2
2018-03-31
2017-12-31
2017-09-30 $-7
2017-06-30 $-3
2017-03-31 $-6
2016-12-31 $-1
2016-09-30 $-1
2016-06-30 $-1
2016-03-31 $-1
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.233B $0.001B
Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company. It is engaged in developing a Nitric Oxide Generator and Delivery System. The company's principal product is AirNOvent which is in clinical stage. Beyond Air Inc., formerly known as AIT Therapeutics Inc., is based in Garden City, New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48